Natco Pharma is currently trading at Rs. 798.00, up by 11.25 points or 1.43% from its previous closing of Rs. 786.75 on the BSE.
The scrip opened at Rs. 800.00 and has touched a high and low of Rs. 815.40 and Rs. 790.05 respectively. So far 29640 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1080.00 on 09-Jun-2017 and a 52 week low of Rs. 671.25 on 10-Aug-2017.
Last one week high and low of the scrip stood at Rs. 815.40 and Rs. 735.00 respectively. The current market cap of the company is Rs. 14881.24 crore.
The promoters holding in the company stood at 48.38%, while Institutions and Non-Institutions held 30.27% and 21.35% respectively.
Natco Pharma has launched a generic version of Posaconazole Injection, 300 mg/16.70 ml, under its brand ‘Posanat’. This is the first time an injection version of this drug available in India. Posanat will be available in 18 mg/ml strength, a formulation for intravenous (IV) use. Posaconazole Injection is sold in the USA market by Merck under its brand name of ‘Noxafil’.
Posaconazole injection is an antifungal agent & used in patients who are at high risk of developing infections due to being severely immunocompromised, such as associated with stem cell transplant or from chemotherapy.
Natco Pharma was promoted as a private company to be in the business of research, developing, manufacturing and marketing of pharmaceutical substances and finished dosage forms for Indian and International markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: